Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Geron Corporation

Market Cap 731M 635M 585M 548M 1.02B 70.03B 1.05B 6.98B 2.7B 33.75B 2.75B 2.69B 117B P/E Ratio 2026 *
-57x
P/E Ratio 2027 * 17.5x
Enterprise Value 710M 616M 568M 532M 995M 68.02B 1.02B 6.78B 2.62B 32.79B 2.67B 2.61B 114B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 1.69x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.64%
1 week-5.79%
Current month-8.80%
1 month-17.99%
3 months-31.33%
6 months-17.99%
Current year-13.64%
1 week 1.08
Extreme 1.08
1.22
1 month 1.08
Extreme 1.08
1.45
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

220,000 0.0343%
05-20Free

Director

220,000 0.0343%
05-20Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+3.64%-5.79%-25.97%-68.33% 731M
+0.57%+1.80%+54.17%+110.76% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+3.81%-5.07%+12.00%-29.52% 15.79B
+0.25%+0.74%+9.37%-39.89% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+5.27%+5.54%+14.25% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +1.92%-0.96%+21.36%+86.01% 21.06B
Weighted average by Cap. +1.55%+0.74%+31.42%+97.33%

Financials

2026 *2027 *
Net sales 234M 203M 187M 175M 327M 22.38B 334M 2.23B 864M 10.79B 877M 859M 37.51B 333M 289M 266M 250M 467M 31.9B 476M 3.18B 1.23B 15.38B 1.25B 1.22B 53.46B
Net income -13.95M -12.11M -11.16M -10.46M -19.54M -1.34B -19.95M -133M -51.55M -644M -52.38M -51.25M -2.24B 46.55M 40.4M 37.24M 34.89M 65.19M 4.46B 66.55M 444M 172M 2.15B 175M 171M 7.47B
Net Debt -20.97M -18.2M -16.77M -15.72M -29.37M -2.01B -29.98M -200M -77.47M -968M -78.72M -77.02M -3.37B -169M -147M -135M -127M -237M -16.18B -242M -1.61B -624M -7.8B -634M -621M -27.12B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
11/06/26 1.140 $ +3.64% 31,746,036
10/06/26 1.100 $ -1.79% 14,737,296
09/06/26 1.120 $ -0.88% 13,609,303
08/06/26 1.130 $ -3.42% 11,184,588
05/06/26 1.170 $ -3.31% 9,600,839
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.140USD
Average target price
3.400USD
Spread / Average Target
+198.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!